Navigation Links
Heart Disease Risks Hit Boys in Teens
Date:4/21/2008

Girls protected by hormones during adolescence, study suggests

MONDAY, April 21 (HealthDay News) -- The first signs that men are at higher risk of heart disease than women appear during the adolescent years, according a new study that tracked boys and girls through their teens.

"This is not what we would have predicted," said Dr. Antoinette Moran, chief of pediatric endocrinology and diabetes at the University of Minnesota Children's Hospital, and lead author of the report in the April 22 issue of Circulation. "Because boys lose fat and gain muscle in adolescence, while girls add body fat."

At the start, 11-year-old boys and girls were similar in body composition, blood pressure and blood levels of lipids (fats). As expected, the percentage of body fat decreased in the boys and increased in the girls over the adolescent years.

Yet the study of the 507 Minneapolis school children found that between the ages of 11 and 19, levels of triglycerides, a type of blood fat associated with cardiovascular disease, increased in the boys and dropped in the girls. Levels of HDL cholesterol, the "good" kind that helps keep arteries clear, went down in boys but rose in girls.

Blood pressure increased in both, but significantly more in boys. And insulin resistance, a marker of cardiovascular risk, which was lower in boys at age 11, rose until the 19-year-old men were more resistant than the women.

But excess weight is of major importance in both sexes, Moran said. "Being overweight or obese can cancel out these relationships and cause increased cardiovascular risk for males and females," she said. "Any protection that the young women had was wiped out by obesity."

A recent study found that more than a third of children and adolescents in the United States are overweight or obese.

The study points toward the importance of hormonal factors in cardiovascular disease risk, Moran explained
'/>"/>

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Gene Variant Protects Black Heart Failure Patients
2. Cardicas C-Port Anastomosis Systems Facilitate Beating Heart Bypass Surgery in Study
3. CardiacAssist, Inc. Announces Five New TandemHeart Centers of Excellence
4. Patients receive heart valve replacements without surgery using high-tech device
5. HeartWare Announces Move to an Expanded, Upgraded Manufacturing Facility
6. Readily available treatment could help prevent heart disease in kidney patients
7. Skin Test Spots Heart Risks in Healthy People
8. Migraines Frequency Influences Heart Attack, Stroke Risk
9. Heartland Information Services Announces Alliance with M*Modal
10. Timing of HRT May Influence Heart Risks
11. Barbra Streisand endows program at Cedars-Sinai womens heart center
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Heart Disease Risks Hit Boys in Teens
Heart Disease Risks Hit Boys in Teens
Breaking Medicine Technology:RetireSafe Announces Intention to Key Vote Senator Dorgan's Drug Importation Amendment (SA 2793) 2Dynatronics Receives 180-Day NASDAQ Extension 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3ASTRO Gildas Club Chicago join to promote cancer survivorship 59515 1Biomedical Research Centre searches for immunological biomarkers 59513 1Biomedical Research Centre searches for immunological biomarkers 59513 2KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 1KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 2KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 3KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification 10371 4